The role of cytochrome P450 2D6 in the metabolism of moclobemide

European Neuropsychopharmacology

Volumn 6, Issue 3, 1996, Pages 225-230

  Härtter, Sebastian ^a   Dingemanse, Jasper ^b   Baier, Dieter ^c   Ziegler, Gismar ^d   Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ROCHE INNOVATION CENTER MUNICH   (Germany)

^d Institute of Psychosomatic Research   (Germany)

Author keywords

CYP2D6; Drug metabolism; MAO A inhibitor; Moclobemide; Pharmacokinetics

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE; DEXTROMETHORPHAN; ISOENZYME; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR;

ADULT; ARTICLE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030221210     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-977X(96)00023-5     Document Type: Article

References (32)

1. Alvan, G. (1991) Clinical consequences of polymorphic drug oxidation. Fundam. Clin. Pharmacol. 5, 209-228.
2. Amrein, R., Guentert, T.W., Dingemanse, J., Lorscheid, T., Stabl, M. and Schmid-Burgk, W. (1992) Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology 106, S24-S31.
3. Audebert, C., Blin, O., Monjanel-Mouterde, S., Auquier, P., Pedarriosse, A.M., Dingemanse, J., Durand, A. and Cano, J.P. (1992) Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers. Eur. J. Clin. Pharmacol. 43, 507-512.
4. Balant, P., Gundert-Remy, U., Boobis, A.R. and von Bahr, C. (1989) Relevance of genetic polymorphism in drug metabolism in the development of new drugs. Eur. J. Clin. Pharmacol. 36, 551-554.
5. Baumann, P., Eap, C.B., Koeb, L., Kasas, A., Blajev, R., Holsboer, E., Bajetta, G., Zöchling, R., Mascetti, R. and Schäublin-Loidl, M. (1994) Pharmacogenetic investigations in moclobemide (MOCL) + thioridazine (THD) vs MOCL + placebo treated depressive patients. Neuropsychopharmacology 10, 75S.
6. Brøsen, K. (1993) The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin. Invest. 71, 1002-1009.
7. Cholerton, S., Daly, A.K. and Idle, J.R. (1992) The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci. 13, 434-439.
8. Da Prada, M., Keller, H.H., Kettler, R., Schaffner, R. and Pieri., M. (1981) A specific and short-acting MAO inhibitor with antidepressant properties. In: Kamijo, K., Usdin, E. and Nagatsu, T. (Eds.), Monoamine Oxidase: Basic and Clinical Aspects. Excerpta Medica, Amsterdam, pp. 183-196.
9. 1. J. Pharmacol. Exp. Ther. 248, 400-414.
10. Derenne, F., Joanne, C.,Vandel, S., Bertschy, G., Volmat, R. and Bechtel, P. (1989) Debrisoquine oxidative phenotyping and psychiatric drug treatment. Eur. J. Clin. Pharmacol. 36, 53-58.
11. Dingemanse, J. (1993) An update of recent moclobemide interaction data. Int. Clin. Psychopharmacol. 7, 167-180.
12. Feifel, N., Kucher, K., Fuchs, L., Jedrychowski, M., Schmidt, E., Antonin, K.-H., Bieck, P.R. and Gleiter, C.H. (1993) Role of cytochrome P4502D6 in the metabolism of brofaromine. Eur. J. Clin. Pharmacol. 45, 265-269.
13. Geschke, R., Koerner, J. and Eggers, H. (1987) Determination of the monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatography. J. Chromatogr, 420, 111-120.
14. Gonzales, F.J. (1992) Human cytochromes P450: problems and prospects. Trends Pharmacol. Sci. 131, 345-352.
15. Gonzales, F.J., Skoda, R.C., Kimura, S., Umeno, M., Zanger, U.M., Nebert, D.W., Gelboin, H.V., Hardwick, J.P. and Meyer, U.A. (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 311, 442-446.
16. Gram, L.F., Brøsen, K., and the Danish University Antidepressant Group (1993) Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Br. J. Clin. Pharmacol. 35, 649-652.
17. Gram, L.F., Guentert, T.W., Grange, S., Vistisen, K. and Brøsen, K. (1995) Moclobemide, a substrate of CYP2C19, and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin. Pharmacol. Ther. 57, 670-677.
18. Guengerich, F.P. (1992) Human cytochrome P-450 enzymes. Life Sci. 50, 1471-1478.
19. Guentert, T.W., Grange, S., Bock, J., Waldburger, R. and Birnboeck, H. (1995) Lack of an important influence of CYP2D6 oxidation status on the pharmacokinetics of moclobemide. Clin. Pharmacol. Ther. 57, 151.
20. Guentert, T.W. and Mayersohn, M. (1994) Clinical-pharmacokinetic profile of moclobemide and its comparison with other MAO-inhibitors. Rev. Contemp. Pharmacother. 5, 19-34.
21. Jauch, R., Griesser, E., Oesterhelt, G., Arnold, W., Meister, W., Ziegler, W.H. and Guentert, T.W. (1990) Biotransformation of moclobemide in humans. Acta Psychiatr. Scand. 82 (Suppl. 360), 87-90.
22. Kerry, N.L., Somogyi, A.A., Bochner, F. and Mikus, G. (1994) The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using humann liver microsomes. Br. J. Clin. Pharmacol. 38, 243-248.
23. Maghoub, A., Idle, J.R., Dring, L.G., Iancaster, R. and Smith, R.L. (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2, 584-586.
24. Mayersohn, M. and Guentert, T.W. (1995) Clinical pharmacokinetics of the monoamine oxidase - A inhibitor moclobemide. Clin. Pharmacokinet. 29, 292-332.
25. Mellstroem, B., Bertilsson, L., Lou, Y.-C., Säwe, J. and Sjoeqvist, F. (1983) Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation. Clin. Pharmacol. Ther. 34: 516-520.
26. Preskorn, S.H. and Magnus, R.D. (1994) Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implication for patient care. Psychopharmacol Bull. 30, 251-259.
27. Schmid, B., Bircher, J. and Preisig, R., Kuepfer, A. (1985) Polymorphic dextromethorphan metabolism: Co-segregation of oxidase O-demethylation with debrisoquine hydroxylation. Clin. Pharmacol. Ther. 38, 618-624.
28. Schoerlin, M.P., Blouin, R.A., Pfefen, J.P. and Guentert, T.W. (1990) Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine. Acta Psychiatr. Scand. 82 (Suppl. 360), 98-100.
29. Schoerlin, M.P., Mayersohn, M., Hoevels, B., Eggers, H., Dellenbach, M. and Pfefen, J.P. (1991) Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Clin. Pharmacol. Ther. 49, 32-38.
30. Silvasti, M., Karttunen, P., Tukiainen, H., Kokkonen, P., Haenninnen, U. and Nykaenen, S. (1987) Pharmacokinetics of dextromethorphan and dextrorphan: a single dose comparison of three preparations in human volunteers. J. Clin. Pharm. Ther. Toxicol. 25, 493-497.
31. Tucker, G.T. (1994) Clinical implications of genetic polymorphism in drug metabolism. J. Pharm. Pharmacol. 46 (Suppl. 1), 417-424.
32. von Moltke, L.L., Greenblatt, D.J., Harmatz, J.S. and Shader, R.I. (1994) Cytochromes in psychopharmacology. J. Clin. Psychopharmacol. 14, 1-4.